Information Provided By: 
Fly News Breaks for October 16, 2015
CEMP
Oct 16, 2015 | 12:27 EDT
Cowen analyst Ritu Baral views today's SOLITAIRE-IV data from Cempra as "solid." Despite "white noise" from perceived safety concerns, U.S. approval is a "very low risk" event, Baral tells investors in a research note. The analyst also pegs European approval at greater than a 90% probability. Baral keeps an Outperform rating on the Cempa with a $53 price target. The clinical-stage pharmaceutical company is down 33%, or $8.80, to $17.98 in midday trading.
News For CEMP From the Last 2 Days
There are no results for your query CEMP
